Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy constant alpha 2 (IGHA2) encodes the constant region of the heavy chain of IgA2, a major subclass of Immunoglobulin A that plays a crucial role in mucosal immunity. IgA2 is secreted primarily at mucosal surfaces and acts as a first line of defense against pathogens. The protein forms part of the antibody structure, contributing to effector functions such as neutralization of pathogens and facilitating their clearance. IGHA2 exhibits structural polymorphisms and works in concert with other immunoglobulin components. Diseases associated with IGHA2 primarily relate to immune disorders and infection, and it may also be implicated as a marker in some hematological cancers[1][2][4][5][7]. Key points: - IGHA2 is *not* a classic drug target like a receptor or enzyme but is an essential component of the adaptive immune system. - There are no approved drugs that target IGHA2 itself; therapeutic relevance is as a biomarker rather than a drug target[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy constant alpha 2 (IGHA2).